• Privacy policy
  • T&C’s
  • FAQ
  • Meet the Team
  • About The London Economic
  • Advertise
TLE ONLINE SHOP!
NEWSLETTER
SUPPORT THE LONDON ECONOMIC
  • TLE
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Food
  • Lifestyle
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
  • TLE
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Food
  • Lifestyle
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
No Result
View All Result
Home Business and Economics Business

Martin Shkreli maybe a Jerk but is a symptom of what’s wrong with Pharma Industry

By Ben Ramanauskas Martin Shkreli has managed to engender feelings of revulsion in the vast majority of the population. He incurred widespread odium when his company, Turing Pharmaceuticals, acquired the drug Daraprim, which is commonly used to treat toxoplasmosis, which kills people with weakened immune systems, such as people suffering from AIDS or undergoing chemotherapy. […]

Joe Mellor by Joe Mellor
February 21, 2016
in Business, News, Politics, Science

By Ben Ramanauskas

Martin Shkreli has managed to engender feelings of revulsion in the vast majority of the population. He incurred widespread odium when his company, Turing Pharmaceuticals, acquired the drug Daraprim, which is commonly used to treat toxoplasmosis, which kills people with weakened immune systems, such as people suffering from AIDS or undergoing chemotherapy. The parasite which causes toxoplasmosis lives inside of one third of the population, in tiny cysts that go undetected because they are quarantined in our brains and livers by our immune systems. When the immune systems of patients deteriorate, though, the parasite is unleashed and attacks the brain and eyes of its host, resulting in blindness, seizures, and loss of cognitive faculties. One study discovered that toxoplasmosis encephalitis affected 25 percent of AIDS patients, of which it killed 84 percent.

It’s easy to dislike Shkreli. The self styled ‘pharma bro’ comes across as a mix between Ferris Bueller and Gordon Gecko. In addition to hiking up the price of Daraprim, it is rumoured that he is planning a move that would raise the price of a drug used to a treat Chagas, a disease mostly affecting Latin American immigrants. Then there was his appearance before Congress; it’s not very often that people find themselves siding with politicians, but Shkreli’s performance as he smugly took the fifth made many sympathise with the exasperated politicians. He relishes in his bad boy image and regularly courts controversy. He recently purchased Wu-Tang Clan’s one-of-a-kind album ‘Once Upon A Time in Shaolin’ for $2m, Since becoming the sole-owner of ‘Once Upon A Time in Shaolin’ in December, he has traded insults with Wu-Tang member Ghostface Killah and threatened to destroy the album.

In a further headline grabbing move, he wrote a letter to Kanye West- which he then tweeted- saying, ‘I am writing to you in hopes of convincing you to withhold the release of your forthcoming studio album. Instead of releasing the product for your millions of fans, I ask you to sell this recording solely to me, for the price of $10, 000, 000. I believe you (and your partners) will find this financial arrangement more attractive than your current course of action.’ He then raised his offer to $15 million, much to the outrage of Kanye West’s fans.

Shkreli is a controversial figure and has been called a “morally bankrupt sociopath,” a “garbage monster,” and “everything that is wrong with capitalism”. This was even before his arrest for securities fraud.

Shkreli’s actions have lead to increased interest in the pharmaceutical industry and the price of medicines. There have been calls from the media, politicians, and the public for increased regulation of the pharmaceutical industry and for prices to be lowered and fixed. Presidential hopeful Hillary Clinton- always desperately looking for a bandwagon to jump on- expressed her disgust at Shkreli’s actions and promised that is she became President, then she would implement a $250 cap on out-of-pocket payments for prescription medications. Clinton also added that, “We’re going to start holding the drug companies accountable to drive down the prices.” Clinton would also end tax breaks for televised advertising and require at least some investment in research and development by companies that are subsidised by tax money.

However, despite Shkreli’s various nefarious activities, the public’s anger towards him is misplaced and the calls of politicians for greater regulation are misguided. From my time advising pharmaceutical companies, I have come to realise that Shkreli’s actions- while morally reprehensible- are an inevitable result of the pharmaceutical industry. He is a symptom of the pharmaceutical industry and is the result of the greed and cronyism which grips the industry.

RelatedPosts

Watch – After billions spent on test and trace Sunak says people ‘trust us with their money’

Lockdown and vaccine sceptics fuming as lockdown and vaccine sceptic journalist gets jab

Police cannot explain ‘unfair’ use of powers against BAME people

Watch: Labour’s Shadow Chancellor won’t say if supports keeping Universal Credit uplift in perpetuity

For example, the costs associated with developing new drugs are astronomical and it is also a high risk endeavour. As a result, pharmaceutical companies must generate huge revenues if they are to remain profitable.

However, the biggest problem- particularly in the United States- is that there is too much regulation and not enough competition. For example, once a drug is developed, the Government grants the pharmaceutical company a patent. This patent gives the pharmaceutical company a monopoly lasting for decades. This, coupled with the cost of production, means that pharmaceutical companies are going to feel justified in charging exorbitant prices.

Furthermore, even when the patent has lapsed- as was the case with Daraprim- the system still makes it easy for pharmaceutical companies to charge inordinate prices. It is often the case that certain medicines are long off patent and are incredibly cheap and easy to manufacture. As a result, one would expect another company to manufacture a generic alternative and sell it at a much cheaper price. However, any potential competitor must conquer a mountain of Government regulation. They have to employ a team of lawyers and scientists and exhaust huge amounts of time and money so that it is often not worth it in the end. As a result, even for long off patent medicines, pharmaceutical companies can easily enjoy a monopoly.

Therefore, if we want to enjoy affordable medicines we need to decrease the regulation of the pharmaceutical industry and encourage greater competition. Martin Shkreli is a person who is easy to dislike. However, we would be better served in directing our anger towards the excessive regulation of the industry which stifles competition, grants monopolies and which allows him to thrive.

Since you are here

Since you are here, we wanted to ask for your help.

Journalism in Britain is under threat. The government is becoming increasingly authoritarian and our media is run by a handful of billionaires, most of whom reside overseas and all of them have strong political allegiances and financial motivations.

Our mission is to hold the powerful to account. It is vital that free media is allowed to exist to expose hypocrisy, corruption, wrongdoing and abuse of power. But we can't do it without you.

If you can afford to contribute a small donation to the site it will help us to continue our work in the best interests of the public. We only ask you to donate what you can afford, with an option to cancel your subscription at any point.

To donate or subscribe to The London Economic, click here.

The TLE shop is also now open, with all profits going to supporting our work.

The shop can be found here.

You can also SUBSCRIBE TO OUR NEWSLETTER .

Support fearless, free, investigative journalism Support fearless, free, investigative journalism Support fearless, free, investigative journalism
Please login to join discussion

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending fromTLE

  • All
  • trending

What If We Got Rid Of Prisons?

Stress, fear and homelessness: The threat looming over families confronted with eviction

File photo dated 07/11/03 of a prison cell.

The Other Prison Pandemic

Latest from TLE

Watch – After billions spent on test and trace Sunak says people ‘trust us with their money’

Credit;PA

Doctor appears in court video call for traffic violation while performing surgery

Credit;PA

Lockdown and vaccine sceptics fuming as lockdown and vaccine sceptic journalist gets jab

Credit;PA

What the parable of the 6.2cm journalist teaches us about NHS data

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

Contact

Editorial enquiries, please contact: jack@thelondoneconomic.com

Commercial enquiries, please contact: advertise@thelondoneconomic.com

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Lifestyle
  • Food
  • Property
  • Travel
  • Tech & Auto
  • About The London Economic
  • Meet the Team
  • Privacy policy

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.